We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
89bio Inc | NASDAQ:ETNB | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.36 | 4.06% | 9.22 | 6.50 | 22.00 | 9.35 | 8.90 | 9.19 | 646,026 | 05:00:10 |
The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.89bio.com/events-and-presentations. The replay of the webcast will be available on the company’s website.
About 89bio
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is being developed for the treatment of NASH and for the treatment of SHTG. BIO89-100 is a specifically engineered glycoPEGylated analog of FGF21 that is currently in a proof of concept Phase 1b/2a clinical trial in patients with NASH or NAFLD and a high risk of NASH. 89bio is headquartered in San Francisco with operations in Herzliya, Israel. Visit 89bio.com for more information.
Investor Contact: Ryan Martins Chief Financial Officer investors@89bio.com
Media Contact: Lori Rosen LDR Communications 917-553-6808 lori@ldrcommunications.com
1 Year 89bio Chart |
1 Month 89bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions